Vir Biotechnology, Inc. — Revenue by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/1e7d2028-bbe0-4520-8b30-56ee7a91cfae/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $68.6M | 2025-01-01 – 2025-12-31 | evidence 0001628280-26-010749 |
| FY 2024 | $74.2M | 2024-01-01 – 2024-12-31 | evidence 0001628280-25-008245 |
| FY 2023 | $86.2M | 2023-01-01 – 2023-12-31 | evidence 0001628280-25-008245 |
| FY 2022 | $1.6B | 2022-01-01 – 2022-12-31 | evidence 0001628280-25-008245 |
| FY 2021 | $1.1B | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-002295 |
| FY 2020 | $76.4M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-008915 |
| FY 2019 | $8.1M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-013194 |
| FY 2018 | $10.7M | 2018-01-01 – 2018-12-31 | evidence 0001564590-20-013194 |
| FY 2017 | $2.7M | 2017-01-01 – 2017-12-31 | evidence 0001564590-20-013194 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Vir Biotechnology, Inc. — all facts · Net Income · Operating Income